PROMOPHARM, a key player in Morocco’s pharmaceutical sector, has announced a major leadership transition following its Ordinary General Assembly on November 13, 2024, at its headquarters in Had-Soualem. The company is embarking on a strategic shift that promises a fresh chapter in its governance and direction.
Ma’moon Al Araideh, who held the dual roles of Chairman and CEO, has officially stepped down. This move aligns with the board’s decision to separate the positions of Chairman and CEO—a governance practice increasingly adopted by leading companies to enhance decision-making and accountability.
Under Al Araideh’s leadership, PROMOPHARM experienced remarkable growth, solidifying its standing as one of Morocco’s pharmaceutical industry leaders. His departure marks the beginning of a new era aimed at fostering specialized and collaborative management.
The Board of Directors has appointed Eyad Abuawad as the new Chairman. With extensive experience and a forward-looking strategic vision, Abuawad will steer the board’s activities until the General Assembly of 2030, where the financial results for the 2029 fiscal year will be reviewed.
Meanwhile, Mohamed Al Alami has been confirmed as CEO. Initially appointed in July 2024, Al Alami has already earned the trust of PROMOPHARM’s leadership. His mandate involves driving the company toward new heights of innovation and market presence.
Adding to the robust leadership team, Mohamed Amine Belghiti Alaoui has been reaffirmed as Deputy CEO in charge of pharmaceutical affairs, a role he has excelled in since 2018. His expertise will be instrumental in navigating the increasingly competitive pharmaceutical landscape.
This strategic reshuffle underscores PROMOPHARM’s commitment to modern governance practices and a sharper focus on sustainable growth. With a restructured leadership team and clear delineation of roles, the company is poised to achieve its ambitious goals in the coming years.
